Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
30 Jul 2024
Historique:
medline: 23 7 2024
pubmed: 23 7 2024
entrez: 23 7 2024
Statut: ppublish

Résumé

Mixed invasive ductal and lobular carcinoma (MDLC) is a rare histologic subtype of breast cancer displaying both E-cadherin positive ductal and E-cadherin negative lobular morphologies within the same tumor, posing challenges with regard to anticipated clinical management. It remains unclear whether these distinct morphologies also have distinct biology and risk of recurrence. Our spatially resolved transcriptomic, genomic, and single-cell profiling revealed clinically significant differences between ductal and lobular tumor regions including distinct intrinsic subtype heterogeneity - e.g., MDLC with triple-negative breast cancer (TNBC) or basal ductal and estrogen receptor positive (ER+) luminal lobular regions, distinct enrichment of cell cycle arrest/senescence and oncogenic (ER and

Identifiants

pubmed: 39042692
doi: 10.1073/pnas.2322068121
doi:

Substances chimiques

Cadherins 0
Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2322068121

Subventions

Organisme : The Dynami Foundation
ID : xxxxxxxxxxxxxx
Organisme : Breast Cancer Research Foundation (BCRF)
ID : xxxxxxxxxxxxxx
Organisme : American Society of Clinical Oncology (ASCO)
ID : xxxxxxxxxxxxxx
Organisme : American Society of Clinical Oncology (ASCO)
ID : xxxxxxxxxxxxxx
Organisme : NCI NIH HHS
ID : P50 CA247749
Pays : United States

Déclaration de conflit d'intérêts

Competing interests statement:The authors declare no competing interest.

Auteurs

Osama Shiraz Shah (OS)

Womens Cancer Research Center at University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA 15213.
Integrative Systems Biology Program, University of Pittsburgh School of Medicine, Pittsburgh PA 15260.

Azadeh Nasrazadani (A)

Womens Cancer Research Center at University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA 15213.
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.

Julia Foldi (J)

Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15260.

Jennifer M Atkinson (JM)

Womens Cancer Research Center at University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA 15213.
Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15260.

Celina G Kleer (CG)

Department of Pathology and Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109.

Priscilla F McAuliffe (PF)

Womens Cancer Research Center at University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA 15213.
Division of Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232.

Tyler J Johnston (TJ)

Department of Computational and Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.

Wayne Stallaert (W)

Department of Computational and Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.

Edaise M da Silva (EM)

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.

Pier Selenica (P)

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.

Higinio Dopeso (H)

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.

Fresia Pareja (F)

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.

Diana Mandelker (D)

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.

Britta Weigelt (B)

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.

Jorge S Reis-Filho (JS)

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.

Rohit Bhargava (R)

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.

Peter C Lucas (PC)

Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine and Science, Rochester, MN 55902.

Adrian V Lee (AV)

Womens Cancer Research Center at University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA 15213.
Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15260.

Steffi Oesterreich (S)

Womens Cancer Research Center at University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA 15213.
Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15260.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH